These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4526298)

  • 1. A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine.
    Momparler RL
    Cancer Res; 1974 Aug; 34(8):1775-87. PubMed ID: 4526298
    [No Abstract]   [Full Text] [Related]  

  • 2. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
    Gustavsson A; Olofsson T
    Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential advances in the clinical use of arabinosyl cytosine.
    Ho DH
    Cancer Treat Rep; 1977 Jul; 61(4):717-22. PubMed ID: 267509
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
    Karp JE; Burke PJ
    Cancer Res; 1976 Oct; 36(10):3600-3. PubMed ID: 1066183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
    Heinemann V; Jehn U
    Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893
    [No Abstract]   [Full Text] [Related]  

  • 6. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).
    Fernandez-Calotti P; Jordheim LP; Giordano M; Dumontet C; Galmarini CM
    Leuk Lymphoma; 2005 Mar; 46(3):335-46. PubMed ID: 15621823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular pharmacology of cytosine arabinoside.
    Kufe DW; Spriggs DR
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):34-48. PubMed ID: 3925560
    [No Abstract]   [Full Text] [Related]  

  • 9. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S; Bhalla K; Rauscher F; Cadman E
    Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside.
    Kufe DW; Spriggs DR; Griffin JD
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):149-58. PubMed ID: 3473675
    [No Abstract]   [Full Text] [Related]  

  • 11. Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro.
    Shackney SE; Ford SS; Occhipinti SJ; Ritch PS; Riccardi R; Erickson BW
    Cancer Res; 1982 Nov; 42(11):4339-47. PubMed ID: 7127279
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple determinants of antimetabolite action in humans.
    Rustum YM
    Bull Cancer; 1979; 66(1):93-6. PubMed ID: 283838
    [No Abstract]   [Full Text] [Related]  

  • 13. Microfluorimetric evaluation of cell kill kinetics with 1-beta-D-arabinofuranosylcytosine.
    Yataganas X; Strife A; Perez A; Clarkson BD
    Cancer Res; 1974 Oct; 34(10):2795-806. PubMed ID: 4528646
    [No Abstract]   [Full Text] [Related]  

  • 14. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
    Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
    [No Abstract]   [Full Text] [Related]  

  • 15. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 16. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
    Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
    Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3?
    Brach MA; Henschler R; Mertelsmann R; Herrmann F
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):39-43. PubMed ID: 1780751
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical studies with 1 beta-D-arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells.
    Creasey WA; DeConti RC; Kaplan SR
    Cancer Res; 1968 Jun; 28(6):1074-81. PubMed ID: 5241767
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.